Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Operating Leases for 7 consecutive years, with $981000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 82.27% year-over-year to $981000.0, compared with a TTM value of $981000.0 through Sep 2025, down 82.27%, and an annual FY2024 reading of $4.0 million, down 57.47% over the prior year.
  • Operating Leases was $981000.0 for Q3 2025 at Bicycle Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $14.4 million in Q1 2023 and bottomed at $981000.0 in Q3 2025.
  • Average Operating Leases over 5 years is $7.6 million, with a median of $8.0 million recorded in 2024.
  • The sharpest move saw Operating Leases soared 2735.92% in 2021, then plummeted 82.27% in 2025.
  • Year by year, Operating Leases stood at $12.1 million in 2021, then decreased by 9.9% to $10.9 million in 2022, then fell by 13.81% to $9.4 million in 2023, then plummeted by 57.47% to $4.0 million in 2024, then plummeted by 75.41% to $981000.0 in 2025.
  • Business Quant data shows Operating Leases for BCYC at $981000.0 in Q3 2025, $1.8 million in Q2 2025, and $2.6 million in Q1 2025.